Influenza
Conditions
Interventions
Jingfang mixture high-dose plus Oseltamivir group:Jingfang mixture (po 20ml tid)
Oseltamivir(po 75mg tid)
Jingfang mixture low-dose plus Oseltamivir group:Jingfang mixture (po 10ml tid)
Oseltamivir grou:Oseltamivir(po 75mg tid)
Jingfang mixture low-dose group:Jingfang mixture (po 10ml tid)
Jingfang mixture high-dose group:Jingfang mixture (po 20ml tid)
Sponsors
Guangdong Provincial Chinese Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 130 Years
Inclusion criteria
Inclusion criteria: (1)Age =65 years old (2)Diagnosed as influenza (3)Diagnosed as Wind-Cold Syndrome (4)Prescription is in line with the medication regimen of protocol (5)Duration of illness =48 hours (6)Sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1)Severe or critical influenza (2)Patients with other respiratory tract infections such as pharyngeal conjunctival feverherpanginapurulent tonsllitisetc. (3)Patients with influenza complicationsincluding bacterial sinusitisotitis mediabronchitispneumoniaetc. (4)Have regularly usse anti-influenza virus drugs within 48 hours before this visit (5)Pregnant and lactating women (6)Patents with immunocompromised diseasetumors and inmunosupresed or deficientsuch as long-term use of hormones or immunosuppressantshuman inmunodeficiency virus infetion (7)Patients with serious primary diseases of the heartbrainliverkidneyhematopoietic and other systems (8)Those who are allergic to the observed drugs and ingredients (9)Those who have participated in any other drug or device trials in the last one month (10)Those judged by other investigators to affect the observation and safety of drug efficacy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to resolution of influenza symptoms; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients hospitalized dueto influenza progression;Proportion of patients who became critically ill with influenza;Incidence of influenza complications;Time for complete deferment of fever;Remission rate and duration of individual symptoms;TCM syndrome evaluation;Dosage and proportion of antipyretic analgesics; | — |
Countries
China
Contacts
Public ContactZhongde Zhang
Guangdong Provincial Chinese Hospital
Outcome results
None listed